Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 10091 

to the purpose of the visit and provide 

a verbal refusal of entry. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1

Activity Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Number of 

non-respondents 

Number of 

responses per 

non-respondent 

Total annual 

non-responses 

Average burden 

per response 

Total 

hours 

2023–2024 Data Collection (Healthcare Facilities)—Completion of Sections 1 and 3.400 1 400 ............................ .......................... .......................... 2.5 .......................... 1,000 

2023–2024 Data Collection (Schools)—Completion of Sections 1 and 3.400 1 400 ............................ .......................... .......................... 2 ............................. 800 

2023–2024 Data Collection (Retail Food Stores)— 

Completion of Sections 1 and 3.

400 1 400 ............................ .......................... .......................... 3 ............................. 1,200 

2023–2024 Data Collection-Completion of Section 

2—All Facility Types.

1,200 1 1,200 ............................ .......................... .......................... 0.5 (30 minutes) ..... 600 

2023–2024 Data Collection-Entry Refusals—All 

Facility Types.

...................... .......................... ...................... 24 1 24 0.08 (5 minutes) ..... 1.92 

Total ................................................................. 3,601.92 .......................... ...................... ............................ .......................... .......................... ................................ ................

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Based on a review of the information 

collection since our last request for 

OMB approval, we have made no 

adjustments to our burden estimate. 

II. References 

The following references are on 

display in the Dockets Management 

Staff (see ADDRESSES) and are available 

for viewing by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday; they are also available 

electronically at https://

www.regulations.gov. FDA has verified 

the website addresses, as of the date this 

document publishes in the Federal 

Register, but websites are subject to 

change over time. 

1. ‘‘Report of the FDA Retail Food Program 

Database of Foodborne Illness Risk 

Factors (2000).’’ Available at: https://

wayback.archive-it.org/7993/ 

20170406023019/https://www.fda.gov/ 

downloads/Food/GuidanceRegulation/ 

UCM123546.pdf. 

2. ‘‘FDA Report on the Occurrence of 

Foodborne Illness Risk Factors in 

Selected Institutional Foodservice, 

Restaurant, and Retail Food Store 

Facility Types (2004).’’ Available at: 

https://wayback.archive-it.org/7993/ 

20170406023011/https://www.fda.gov/ 

downloads/Food/GuidanceRegulation/ 

RetailFoodProtection/

FoodborneIllnessRiskFactorReduction/ 

UCM423850.pdf. 

3. ‘‘FDA Report on the Occurrence of 

Foodborne Illness Risk Factors in 

Selected Institutional Foodservice, 

Restaurant, and Retail Food Store 

Facility Types (2009).’’ Available at: 

https://wayback.archive-it.org/7993/ 

20170406023004/https://www.fda.gov/ 

Food/GuidanceRegulation/

RetailFoodProtection/ 

FoodborneIllnessRiskFactorReduction/ 

ucm224321.htm. 

4. FDA National Retail Food Team. ‘‘FDA 

Trend Analysis Report on the 

Occurrence of Foodborne Illness Risk 

Factors in Selected Institutional 

Foodservice, Restaurant, and Retail Food 

Store Facility Types (1998–2008).’’ 

(2010). Available at: https://

wayback.archive-it.org/7993/ 

20170406022950/https://www.fda.gov/ 

Food/GuidanceRegulation/

RetailFoodProtection/ 

FoodborneIllnessRiskFactorReduction/ 

ucm223293.htm. 

5. ‘‘FDA Food Code.’’ Available at: https://

www.fda.gov/food/retail-food-protection/ 

fda-food-code. 

Dated: February 11, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–03248 Filed 2–17–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute on 

Aging Special Emphasis Panel, March 

15, 2021, 10:00 a.m. to March 15, 2021, 

07:00 p.m., National Institute on Aging, 

Gateway Building, 7201 Wisconsin 

Avenue, Bethesda, MD 20892, which 

was published in the Federal Register 

on February 04, 2021, 86 FR 8215. 

The meeting notice is amended to 

change the date of the meeting from 

March 1, 2021 to March 15, 2021. The 

meeting is closed to the public. 

Dated: February 12, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03255 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Meeting of the National Advisory 

Council for Healthcare Research and 

Quality 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of public meeting. 

SUMMARY: This notice announces a 

meeting of the National Advisory 

Council for Healthcare Research and 

Quality. 

DATES: The meeting will be held on 

Thursday, March 18, 2021, from 10:00 

a.m. to 2:00 p.m. 

ADDRESSES: The meeting will be held 

virtually. 

FOR FURTHER INFORMATION CONTACT: 

Jaime Zimmerman, Designated 

Management Official, at the Agency for 

Healthcare Research and Quality, 5600 

Fishers Lane, Mail Stop 06E37A, 

Rockville, Maryland, 857, (301) 427– 

1456. For press-related information, 

please contact Bruce Seeman at (301) 

427–1998 or Bruce.Seeman@

AHRQ.hhs.gov. 

Closed captioning will be provided 

during the meeting. If another 

reasonable accommodation for a 

disability is needed, please contact the 

Food and Drug Administration (FDA) 

Office of Equal Employment 

Opportunity and Diversity Management 

on (301) 827–4840, no later than 

Monday, March 1, 2021. The agenda, 

roster, and minutes will be available 

from Ms. Heather Phelps, Committee 

Management Officer, Agency for 

Healthcare Research and Quality, 5600 

Fishers Lane, Rockville, Maryland, 

20857. Ms. Phelps’ phone number is 

(301) 427–1128. 

SUPPLEMENTARY INFORMATION: 


jbell on DSKJLSW7X2PROD with NOTICES
10092 Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 

I. Purpose 

In accordance with section 10(a) of 

the Federal Advisory Committee Act, 5 

U.S.C. App., this notice announces a 

meeting of the National Advisory 

Council for Healthcare Research and 

Quality (the Council). The Council is 

authorized by Section 941 of the Public 

Health Service Act, 42 U.S.C. 299c. In 

accordance with its statutory mandate, 

the Council is to advise the Secretary of 

the Department of Health and Human 

Services and the Director of AHRQ on 

matters related to AHRQ’s conduct of its 

mission including providing guidance 

on (A) priorities for health care research, 

(B) the field of health care research 

including training needs and 

information dissemination on health 

care quality and (C) the role of the 

Agency in light of private sector activity 

and opportunities for public private 

partnerships. The Council is composed 

of members of the public, appointed by 

the Secretary, and Federal ex-officio 

members specified in the authorizing 

legislation. 

II. Agenda 

On Thursday, March 18, 2021, the 

Council meeting will convene at 10:00 

a.m., with the call to order by the 

Council Chair and approval of previous 

Council summary notes. The meeting 

will begin with an update on AHRQ’s 

recent accomplishments in Health 

Systems Research, Practice 

Improvement, Data and Analytics, and 

achieving organizational excellence. 

The agenda will also include a 

discussion of communication and value 

of health systems research, an update on 

PCOR Trust Funds, and a discussion of 

how AHRQ may advance health equity. 

The meeting will adjourn at 2:00 p.m. 

The meeting is open to the public. For 

information regarding how to access the 

meeting as well as other meeting details, 

including information on how to make 

a public comment, please go to https:// 

www.ahrq.gov/news/events/nac/. The 

final agenda will be available on the 

AHRQ website no later than Thursday, 

March 11, 2021. 

Dated: February 11, 2021. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2021–03182 Filed 2–17–21; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

PAR 20–280, Cooperative Research 

Agreements to the World Trade Center 

Health Program (U01); and RFA OH– 

21–004, Exploratory/Developmental 

Grants Related to the World Trade 

Center Health Program (R21); 

Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—Funding 

Opportunity Announcement (FOA), 

PAR 20–280, Cooperative Research 

Agreements to the World Trade Center 

Health Program (U01); and RFA OH–21– 

004, Exploratory/Developmental Grants 

Related to the World Trade Center 

Health Program (R21), March 16–17, 

2021, from 9:00 a.m.–6:00 p.m., EDT; 

and March 18, 2021, from 9:00 a.m.– 

12:00 p.m., EDT, in the original FRN. 

The virtual meeting was published in 

the Federal Register on Monday, 

January 11, 2021, Volume 86, Number 6, 

pages 1975–1976. 

The virtual meeting is being amended 

to change the dates and times and 

should read as follows: 

Dates and Times: March 16–17, 2021, 

from 1:00 p.m.–5:00 p.m., EDT. 

The meeting is closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Marilyn Ridenour B.S.N., M.B.A., 

M.P.H., C.P.H., C.I.C., CAPT, USPHS, 

Scientific Review Officer, CDC, National 

Institute for Occupational Safety and 

Health, 1095 Willowdale Road, Mailstop 

1811, Morgantown, West Virginia 

26505, Telephone (304) 285–5879. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–03230 Filed 2–17–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

R13 Conference Grant Review. 

Date: April 1, 2021. 

Time: 11:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Preethy Nayar, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021 Bethesda, MD 20892, 301–443–4577 

nayarp2@csr.nih.gov 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: February 11, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03187 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Allogeneic Therapy for 

the Treatment of Autoimmune Disease 

Using Chimeric Antigen Receptors 

Targeting CD19 

AGENCY: National Institutes of Health, 

HHS. 


jbell on DSKJLSW7X2PROD with NOTICES